Hence, it has been proposed that the effectiveness of treatment for HCC could be improved by combining Sorafenib with other therapies such as PI3K/mTOR inhibitors and STAT3 blockers, offer promising strategies to enhance Sorafenib efficacy and overcome resistance [46], [47], [48], [49]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.